IL18 and neoplasm: These observations have been supported by recent findings in which CAR T cell activity was enhanced in the presence of IL-18, with IL-18 released by engineered CAR-T cells promoting acute inflammation and reducing exhausted cell numbers within the tumour, resulting in a more effective immune response against established tumours [64].